Prognostic evaluation of preoperative serum tumor marker‐negative cases in non‐small cell lung cancer: A retrospective study

Background The role of various serum tumor markers (TMs) has been reported in non‐small cell lung cancer (NSCLC). However, the prognosis of patients with multiple TM‐negative NSCLC remain unclear. Aims This study aimed to describe the characteristics and outcomes of patients with NSCLC undergoing su...

Full description

Saved in:
Bibliographic Details
Published in:Cancer reports 2023-02, Vol.6 (2), p.e1696-n/a
Main Authors: Onuki, Yuichiro, Matsubara, Hirochika, Koizumi, Ryunosuke, Muto, Mamoru, Sasanuma, Harunobu, Sato, Daisuke, Sugimura, Aya, Uchida, Tsuyoshi, Matsuoka, Hiroyasu, Nakajima, Hiroyuki
Format: Article
Language:English
Subjects:
Antigens
biology
Biomarkers
Biomarkers, Tumor
CA-19-9 Antigen
Cancer therapies
Carcinoembryonic Antigen
Carcinoma, Non-Small-Cell Lung - pathology
Chronic obstructive pulmonary disease
Comorbidity
Humans
Lung cancer
Lung Neoplasms - pathology
Medical prognosis
Original
Pneumonia
Prognosis
Retrospective Studies
Review boards
Squamous cell carcinoma
Surgery
Tomography
tumor markers
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The role of various serum tumor markers (TMs) has been reported in non‐small cell lung cancer (NSCLC). However, the prognosis of patients with multiple TM‐negative NSCLC remain unclear. Aims This study aimed to describe the characteristics and outcomes of patients with NSCLC undergoing surgery and to investigate their prognostic association with preoperative serum TM‐negative cases. Methods and results We retrospectively evaluated 442 patients who underwent complete resection of stage I NSCLC between January 2004 and December 2019. These 442 patients were classified into a group whose preoperative serum levels of carcinoembryonic antigen (CEA), cytokeratin‐19 fragment (CYFRA21‐1), carbohydrate antigen 19‐9 (CA19‐9), and squamous cell carcinoma antigen (SCC Ag) were all negative (TM‐negative group; n = 249, 56%) and a group with at least one positive marker (TM‐positive group; n = 193, 44%). Among all patients, the TM‐negative group showed higher 5‐year recurrence‐free survival (RFS) (92.6% vs. 79.1%; p 
ISSN:2573-8348
2573-8348
DOI:10.1002/cnr2.1696